PA
TVTX icon

Profund Advisors’s Travere Therapeutics TVTX Stock Holding History

Profund Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Sell
30,574
-37,344
-55% -$1.66M 0.05% 231
2026
Q1 		$2.02M Buy
67,918
+5,314
+8% +$159K 0.07% 202
2025
Q4 		$2.39M Buy
62,604
+42,366
+209% +$1.38M 0.07% 181
2025
Q3 		$484K Sell
20,238
-6,015
-23% -$113K 0.02% 526
2025
Q2 		$389K Sell
26,253
-4,025
-13% -$66.7K 0.01% 556
2025
Q1 		$543K Sell
30,278
-3,803
-11% -$77.2K 0.02% 444
2024
Q4 		$594K Buy
34,081
+15,181
+80% +$269K 0.02% 429
2024
Q3 		$264K Sell
18,900
-14,936
-44% -$156K 0.01% 873
2024
Q2 		$278K Sell
33,836
-57,898
-63% -$390K 0.01% 764
2024
Q1 		$707K Buy
91,734
+22,247
+32% +$188K 0.03% 459
2023
Q4 		$625K Buy
69,487
+8,504
+14% +$61.9K 0.03% 448
2023
Q3 		$545K Sell
60,983
-28,947
-32% -$408K 0.03% 444
2023
Q2 		$1.38M Buy
89,930
+29,401
+49% +$535K 0.07% 234
2023
Q1 		$1.36M Buy
+60,529
New +$1.29M 0.08% 207

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Profund Advisors's TVTX Position: Q2 2026 in Review

Profund Advisors reduced its Travere Therapeutics (TVTX) stake by 55% in Q2 2026, selling an estimated $1.66M and leaving 30,574 shares worth $1.74M. The position accounts for 0.05% of the portfolio, ranked #231.

Profund Advisors first reported a position in TVTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.39M in Q4 2025. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Profund Advisors held 30,574 shares of Travere Therapeutics worth $1.74M as of Q2 2026.
  • Profund Advisors sold 37,344 Travere Therapeutics shares in Q2 2026, an estimated $1.66M.
  • Travere Therapeutics made up 0.05% of Profund Advisors's portfolio in Q2 2026, its #231 holding.
  • Profund Advisors first reported a position in Travere Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's Travere Therapeutics position peaked at $2.39M in Q4 2025.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.